ERBB2 and breast carcinoma: In a recent important study in the field, Yerushalmi et al.[9] reported that IGF1R overexpression was associated with better breast cancer-specific survival (BCSS) in patients with luminal B tumors, which is in accordance with our results, and with worse BCSS in patients with HER2-enriched tumors, which was not confirmed in our cohort.